The First Affiliated Hospital, Jinan University, Guangzhou, China.
Peking University Health Science Center, Peking University, Beijing, China.
Neurol Res. 2021 Dec;43(12):955-960. doi: 10.1080/01616412.2021.1948740. Epub 2021 Jul 11.
: This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources. From January 2013 to December 2019, 83 patients with brain metastases and refractory brain edema were treated with bevacizumab. They were divided into lung cancer group and breast cancer group. The clinical data, the efficacy, and the side effects of bevacizumab were recorded. Magnetic resonance imaging was performed before and after bevacizumab treatment. The volume of tumor and brain edema were measured respectively. After treatment with bevacizumab, 72 cases of refractory brain edema were significantly relieved. The edema control rate was 93.75% in the lung cancer group and 77.14% in the breast cancer group (P < .05). The brain edema volume was significantly reduced after bevacizumab treatment from 198,286.84 ± 60,564.40 to 114,677.71 ± 42,337.38mm (P < .01), and the edema index was reduced from 26.14 ± 7.24 to 17.18 ± 5.14 (P < .01). Hypertension was observed in 14 cases. Bevacizumab could significantly reduce refractory brain edema with a control rate of 86.75%. The efficacy of bevacizumab in the treatment of refractory brain edema caused by lung cancer is better than that of breast cancer.
本回顾性研究探讨了贝伐珠单抗治疗不同来源脑转移瘤伴难治性脑水肿患者的疗效。2013 年 1 月至 2019 年 12 月，83 例脑转移瘤伴难治性脑水肿患者接受贝伐珠单抗治疗。将其分为肺癌组和乳腺癌组，记录患者的临床资料、贝伐珠单抗的疗效和不良反应。于贝伐珠单抗治疗前后行磁共振成像检查，分别测量肿瘤体积和脑水肿体积。贝伐珠单抗治疗后 72 例难治性脑水肿明显缓解，肺癌组脑水肿控制率为 93.75%，乳腺癌组为 77.14%（P<.05）。贝伐珠单抗治疗后脑水肿体积从 198286.84±60564.40mm 减小至 114677.71±42337.38mm（P<.01），水肿指数从 26.14±7.24 减小至 17.18±5.14（P<.01）。14 例出现高血压。贝伐珠单抗能显著减轻难治性脑水肿，控制率为 86.75%，其治疗肺癌所致难治性脑水肿的疗效优于乳腺癌。
